Hyderabad, October 23, 2025: Researchers at IIT Hyderabad have created an innovative AI-powered platform called RadGLO that enables cancer specialists to diagnose and analyze brain tumours non-invasively using routine MRI scans. This breakthrough promises safer, quicker, and highly personalized treatment planning for glioma patients without the risks of surgical biopsies.
Published recently in the journal Precision Oncology, the platform extracts detailed radiomic features—quantitative data on tumour shape, texture, and intensity—from MRI images. These features offer insights comparable to genetic analyses, helping doctors determine tumour aggressiveness, predict patient survival, and tailor treatment strategies.
RadGLO is complemented by RaSPr (Radiomic Survival Predictor), which classifies patients into high-risk and low-risk groups, further aiding physicians in decision-making. The interactive web-based RadGLO platform links MRI-visible tumour features to nearly 20,000 genes, allowing a deeper understanding of tumour progression.
Oncologists simply upload an MRI scan to receive automated risk assessments and genetic correlations, revolutionizing brain tumour diagnosis and prognosis with a non-invasive approach. The research team includes Kavita Kundal, Dr. K. Divya Rani, Vinodini D, Dr. Neeraj Kumar, and Dr. Rahul Kumar.
RadGLO represents a significant leap towards precision medicine in oncology, empowering clinicians globally to deliver personalized, data-driven treatment for brain cancer patients.
